Guangdong Jiaying Pharmaceutical Co Ltd (002198) - Net Assets

Latest as of March 2026: CN¥730.39 Million CNY ≈ $106.88 Million USD

Based on the latest financial reports, Guangdong Jiaying Pharmaceutical Co Ltd (002198) has net assets worth CN¥730.39 Million CNY (≈ $106.88 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥892.78 Million ≈ $130.64 Million USD) and total liabilities (CN¥162.39 Million ≈ $23.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Guangdong Jiaying Pharmaceutical Co Ltd (002198) total assets for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥730.39 Million
% of Total Assets	81.81%
Annual Growth Rate	13.64%
5-Year Change	4.89%
10-Year Change	-27.1%
Growth Volatility	51.42

Guangdong Jiaying Pharmaceutical Co Ltd - Net Assets Trend (2004–2025)

This chart illustrates how Guangdong Jiaying Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check 002198 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Guangdong Jiaying Pharmaceutical Co Ltd (2004–2025)

The table below shows the annual net assets of Guangdong Jiaying Pharmaceutical Co Ltd from 2004 to 2025. For live valuation and market cap data, see Guangdong Jiaying Pharmaceutical Co Ltd market cap and net worth.

Year	Net Assets	Change
2025-12-31	CN¥717.93 Million ≈ $105.06 Million	-5.31%
2024-12-31	CN¥758.22 Million ≈ $110.95 Million	-0.62%
2023-12-31	CN¥762.98 Million ≈ $111.65 Million	+4.75%
2022-12-31	CN¥728.42 Million ≈ $106.59 Million	+6.42%
2021-12-31	CN¥684.48 Million ≈ $100.16 Million	+0.22%
2020-12-31	CN¥683.01 Million ≈ $99.95 Million	+2.99%
2019-12-31	CN¥663.17 Million ≈ $97.04 Million	-15.56%
2018-12-31	CN¥785.35 Million ≈ $114.92 Million	+4.74%
2017-12-31	CN¥749.81 Million ≈ $109.72 Million	-23.87%
2016-12-31	CN¥984.87 Million ≈ $144.12 Million	+5.93%
2015-12-31	CN¥929.70 Million ≈ $136.04 Million	+7.69%
2014-12-31	CN¥863.35 Million ≈ $126.33 Million	+6.63%
2013-12-31	CN¥809.66 Million ≈ $118.48 Million	+191.16%
2012-12-31	CN¥278.08 Million ≈ $40.69 Million	+2.80%
2011-12-31	CN¥270.51 Million ≈ $39.58 Million	+4.66%
2010-12-31	CN¥258.47 Million ≈ $37.82 Million	+7.06%
2009-12-31	CN¥241.42 Million ≈ $35.33 Million	+6.66%
2008-12-31	CN¥226.35 Million ≈ $33.12 Million	+6.45%
2007-12-31	CN¥212.62 Million ≈ $31.11 Million	+157.33%
2006-12-31	CN¥82.63 Million ≈ $12.09 Million	+28.32%
2005-12-31	CN¥64.39 Million ≈ $9.42 Million	+31.49%
2004-12-31	CN¥48.97 Million ≈ $7.17 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guangdong Jiaying Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 4277.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥129.50 Million	18.04%
Other Components	CN¥588.43 Million	81.96%
Total Equity	CN¥717.93 Million	100.00%

Guangdong Jiaying Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Guangdong Jiaying Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
EMS Limited NSE:EMSLIMITED	$248.84 Million
P.C.B Tec TA:PCBT	$248.85 Million
Skel fjárfestingafélag hf. IC:SKEL	$248.86 Million
Bioteque TWO:4107	$248.89 Million
Nanning Baling Technology SHE:002592	$248.76 Million
Falcon Oil & Gas Ltd. V:FO	$248.72 Million
JNK India Ltd NSE:JNKINDIA	$248.61 Million
Iljin HySolus Co Ltd KO:271940	$248.55 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guangdong Jiaying Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 758,220,755 to 717,929,630, a change of -40,291,125 (-5.3%).
Net income of 30,477,433 contributed positively to equity growth.
Other comprehensive income decreased equity by 27,767,450.
Other factors decreased equity by 43,001,108.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥30.48 Million	+4.25%
Other Comprehensive Income	CN¥-27.77 Million	-3.87%
Other Changes	CN¥-43.00 Million	-5.99%
Total Change	CN¥-	-5.31%

Book Value vs Market Value Analysis

This analysis compares Guangdong Jiaying Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.37x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 18.94x to 2.37x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-12-31	CN¥0.18	CN¥3.35	x
2005-12-31	CN¥0.21	CN¥3.35	x
2006-12-31	CN¥0.27	CN¥3.35	x
2007-12-31	CN¥0.70	CN¥3.35	x
2008-12-31	CN¥0.56	CN¥3.35	x
2009-12-31	CN¥0.58	CN¥3.35	x
2010-12-31	CN¥0.63	CN¥3.35	x
2011-12-31	CN¥0.66	CN¥3.35	x
2012-12-31	CN¥0.68	CN¥3.35	x
2013-12-31	CN¥1.90	CN¥3.35	x
2014-12-31	CN¥1.70	CN¥3.35	x
2015-12-31	CN¥1.83	CN¥3.35	x
2016-12-31	CN¥1.94	CN¥3.35	x
2017-12-31	CN¥1.48	CN¥3.35	x
2018-12-31	CN¥1.55	CN¥3.35	x
2019-12-31	CN¥1.31	CN¥3.35	x
2020-12-31	CN¥1.35	CN¥3.35	x
2021-12-31	CN¥1.34	CN¥3.35	x
2022-12-31	CN¥1.44	CN¥3.35	x
2023-12-31	CN¥1.50	CN¥3.35	x
2024-12-31	CN¥1.49	CN¥3.35	x
2025-12-31	CN¥1.41	CN¥3.35	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guangdong Jiaying Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.25%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.94%
• Asset Turnover: 0.45x
• Equity Multiplier: 1.18x
Recent ROE (4.25%) is below the historical average (5.31%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	5.65%	7.39%	0.52x	1.47x	CN¥-2.13 Million
2005	23.95%	28.37%	0.60x	1.42x	CN¥8.98 Million
2006	26.76%	35.28%	0.52x	1.45x	CN¥13.85 Million
2007	11.48%	37.81%	0.26x	1.15x	CN¥3.16 Million
2008	6.06%	20.68%	0.28x	1.04x	CN¥-8.91 Million
2009	6.25%	24.19%	0.25x	1.05x	CN¥-9.06 Million
2010	9.77%	33.55%	0.25x	1.16x	CN¥-600.14K
2011	7.48%	23.56%	0.28x	1.13x	CN¥-6.81 Million
2012	2.72%	7.24%	0.33x	1.13x	CN¥-20.24 Million
2013	17.23%	61.52%	0.25x	1.14x	CN¥58.52 Million
2014	8.53%	13.02%	0.55x	1.20x	CN¥-12.68 Million
2015	7.14%	13.95%	0.45x	1.13x	CN¥-26.62 Million
2016	5.60%	12.26%	0.41x	1.12x	CN¥-43.32 Million
2017	-28.64%	-45.88%	0.53x	1.17x	CN¥-289.74 Million
2018	4.57%	6.68%	0.60x	1.13x	CN¥-42.66 Million
2019	-18.42%	-24.41%	0.58x	1.29x	CN¥-188.50 Million
2020	2.90%	3.64%	0.67x	1.18x	CN¥-48.46 Million
2021	0.22%	0.26%	0.71x	1.18x	CN¥-66.97 Million
2022	6.03%	6.66%	0.78x	1.16x	CN¥-28.91 Million
2023	4.50%	6.44%	0.63x	1.11x	CN¥-41.98 Million
2024	2.72%	5.48%	0.45x	1.11x	CN¥-55.21 Million
2025	4.25%	7.94%	0.45x	1.18x	CN¥-41.32 Million

Industry Comparison

This section compares Guangdong Jiaying Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $2,436,453,686
Average return on equity (ROE) among peers: -1.65%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guangdong Jiaying Pharmaceutical Co Ltd (002198)	CN¥730.39 Million	5.65%	0.22x	$248.79 Million
Zhejiang Int'L Group Co Ltd (000411)	$2.08 Billion	4.50%	3.32x	$734.68 Million
Zhejiang Zhenyuan Share Co Ltd (000705)	$2.00 Billion	4.08%	0.47x	$325.63 Million
Hunan Jingfeng Pharmaceutical (000908)	$-15.13 Million	0.00%	0.00x	$775.01 Million
Hubei Guangji Pharmaceutical Co Ltd (000952)	$486.87 Million	5.05%	0.56x	$293.79 Million
Yifan Xinfu Pharmaceutical Co Ltd (002019)	$469.52 Million	-49.05%	1.48x	$1.84 Billion
Sichuan Kelun Pharmaceutical Co Ltd (002422)	$11.98 Billion	6.25%	1.34x	$9.62 Billion
Chongqing Lummy Pharmaceutical (300006)	$1.65 Billion	-9.38%	1.12x	$763.29 Million
Zhejiang Jolly Pharmaceutical Co Ltd (300181)	$1.47 Billion	4.89%	0.38x	$1.48 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357)	$1.80 Billion	18.81%	0.08x	$1.80 Billion

About Guangdong Jiaying Pharmaceutical Co Ltd

SHE:002198 China Drug Manufacturers - General

Market Cap

$248.79 Million

CN¥1.70 Billion CNY

Market Cap Rank

#15636 Global

#4571 in China

Share Price

CN¥3.35

Change (1 day)

+2.13%

52-Week Range

CN¥2.96 - CN¥8.43

All Time High

CN¥14.97